Immunomodulation to Fight Cancer Spread
Official title: Interrogating Immunomodulation for Anti-Metastatic Therapy
Funded at Wistar Institute · NIH-11577575 · Data updated 2026-11-12
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 3, 2025 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $249,000 |
| NIH project number | 4R00CA293137-03 |
| Project ID | NIH-11577575 on NIH RePORTER |
Who could benefit from this research
✓Could help
This program is for a postdoctoral researcher; it does not specify patient participants for this grant.
✕Less likely to help
Patients would not directly join this grant as subjects, but eventual therapies could benefit those with cancer.
What this research studies
This program trains a postdoctoral scientist at Stanford with mentors who have deep cancer and immunology expertise. The work combines advanced single-cell RNA sequencing over time with high-throughput drug screening to uncover how tumor-immune interactions promote metastasis. The goal is to generate first-generation anti-metastatic immunotherapies and build skills for independent, translational cancer research. The training emphasizes career development, technical breadth, and preparation for future leadership in the field. The research is designed to be conducted in a real-world, collaborative environment with access to top resources at Stanford and the mentors’ labs at Wistar.
Why it matters
Potential benefit: If successful, findings could guide new immunotherapies that prevent or limit cancer spread and improve patient outcomes.
How similar studies have gone: Previous work using longitudinal single-cell sequencing and compound screening has shown promise in revealing immune-related drivers of metastasis.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Mcginnis, Christopher Swart — Wistar Institute
- Study coordinator: Mcginnis, Christopher Swart
Related research
Other NIH-funded projects on the same topics.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
-
Neutralizing IFN-I to boost HIV-targeted CAR T cell therapy
A new approach aims to block a specific immune signal (IFN-I) to help HIV-fighting CAR T cells work better in people living with HIV who are on ART.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.